Egypt’s Heart Failure drug market size stood at USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Heart failure refers to complex clinical syndrome having certain signs and symptoms which are a result of structural and functional cardiac aberrations.
The disease pattern in Egypt is largely mirroring that of developed countries and the market for the treatment of chronic diseases (CVDs) is growing due to large demand. In Egypt, cardiovascular disease (CVD) has been the leading cause of premature death since the 1990s. In 2017, CVD accounted for 46.2% of the overall mortality in Egypt.
Cardiovascular diseases and heart diseases have become the leading causes of death and DALYs in Egypt and continuously rising. The heart failure treatment market is also experiencing immense growth in the market. The leading factors for this rise are the sedentary lifestyle and others factors such as excessive alcohol consumption, smoking, unhealthy diet, obesity, and lack of exercise.
Further, the key leading companies have increased their investment in research and development of heart problems and their treatment which will quench the thrust in demand for advanced and effective treatment among the people.